Angela was in her early 20s when she came to Dante Labs desperate for help in diagnosing her strange symptoms. Dante Labs sequenced Angela’s whole genome ultimately diagnosing Angela with a rare disease, bringing her out of a years long diagnostic odyssey.
While grateful for finally having a diagnosis, unfortunately, there were no drugs or treatments for Angela’s condition. Dante Labs came together as a team, recognizing the Company’s responsibility to Angela, its capabilities in R&D technology, and the strength of its platform to expand into drug discovery and development.
The Company was able to launch Dante’s Discovery program with a rare disease EMA orphan drug application now in the late stages of its non-regulatory pre-clinical phase to treat Angela’s rare disease.
With a pipeline of six drug discovery programs, Dante Labs is working to deliver genomic solutions from diagnosis to treatment to prevention, so people like Angela can lead healthier lives.
